Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 6/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.60 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4411200 | 1.00 | S1PR2 (0.60) | S1PR2S1PR1GPR84ALDH1A1S1PR3 | |
| SCHEMBL626959 | 1.00 | S1PR2 (0.60) | S1PR2S1PR1GPR84ALDH1A1S1PR3 | |
| SCHEMBL5102963 | 0.98 | S1PR2 (0.63) | S1PR2S1PR1GPR84ALDH1A1S1PR3 | |
| SCHEMBL6757021 | 0.98 | S1PR2 (0.63) | S1PR2S1PR1GPR84ALDH1A1S1PR3 | |
| SCHEMBL11629828 | 0.98 | S1PR2 (0.63) | S1PR2S1PR1GPR84ALDH1A1S1PR3 | |
| SCHEMBL11437074 | 0.98 | S1PR2 (0.63) | S1PR2S1PR1GPR84ALDH1A1S1PR3 | |
| SCHEMBL5419098 | 0.98 | S1PR2 (0.63) | S1PR2S1PR1GPR84ALDH1A1S1PR3 | |
| SCHEMBL10804885 | 0.98 | S1PR2 (0.63) | S1PR2S1PR1GPR84ALDH1A1S1PR3 | |
| SCHEMBL22660994 | 0.98 | S1PR2 (0.63) | S1PR2S1PR1GPR84ALDH1A1S1PR3 | |
| SCHEMBL4390623 | 0.98 | S1PR2 (0.63) | S1PR2S1PR1GPR84ALDH1A1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | claimed |
| EP-2836485-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2018-01-10 | — | — | EP | claimed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | claimed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | claimed |
| US-9512139-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2016-12-06 | — | — | US | claimed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | claimed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | claimed |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-10-25 | — | — | US | claimed |
| EP-2499148-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2012-09-19 | — | — | EP | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| WO-2011014973-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2011-02-10 | — | — | WO | claimed |
| WO-2024029242-A1 | NOVEL LRP1-BINDING PEPTIDE | 一丸ファルコス株式会社 | 2024-02-08 | — | — | WO | disclosed |
| US-20230174582-A1 | VIPR2 ANTAGONIST PEPTIDE | ICHIMARU PHARCOS CO., LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| EP-4137502-A1 | VIPR2 ANTAGONIST PEPTIDE | Ichimaru Pharcos Co., Ltd. (JP) | 2023-02-22 | — | — | EP | disclosed |
| EP-1163222-A1 | PROCESS OF PREPARING 3S-3-AMINO-3-ARYL PROPIONIC ACID AND DERIVATIVES THEREOF | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2001-12-19 | — | — | EP | disclosed |
| US-6331552-B1 | THERAPY AND PROPHYLAXIS OF INFLAMMATORY DISORDERS, FOR EXAMPLE OF RHEUMATOID ARTHRITIS, OR OF ALLERGIC DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-12-18 | — | — | US | disclosed |
| WO-2000056715-A1 | PROCESS OF PREPARING 3S-3-AMINO-3-ARYL PROPIONIC ACID AND DERIVATIVES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
| WO-2000056715-A1 | PROCESS OF PREPARING 3S-3-AMINO-3-ARYL PROPIONIC ACID AND DERIVATIVES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | S1PR2 433/4885S1PR1 630/4885GPR84 174/4885 |
| US-20230174582-A1 | VIPR2 ANTAGONIST PEPTIDE | VIPR2, NPY2R, NPY5R | S1PR2 1547/4885S1PR1 2447/4885GPR84 1819/4885 |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | S1PR2 1491/4885S1PR1 922/4885GPR84 596/4885 |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | KCNB1, KCNAB1, KCNMB1 | S1PR2 655/4885S1PR1 507/4885GPR84 376/4885 |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | CTSE, CTSB, CTSS | S1PR2 1491/4885S1PR1 922/4885GPR84 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.